Monkey Pox Treatment Market Report 2025

This Monkey Pox Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The monkey pox treatment market size has grown rapidly in recent years. It will grow from $0.09 billion in 2024 to $0.1 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to outbreaks in endemic regions, zoonotic transmission awareness, smallpox eradication legacy, public health initiatives, emergence of human cases.

The monkey pox treatment market size is expected to see rapid growth in the next few years. It will grow to $0.17 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to globalization and travel, government funding and support, biotech and pharmaceutical investment, public health surveillance, and regulatory approvals. Major trends in the forecast period include antiviral drug development, use of smallpox vaccines, monoclonal antibodies, combination therapies, and long-term immunity research.

The monkeypox (mpox) treatment market is expected to expand due to the rising prevalence of zoonotic infections. Zoonotic infections are diseases that transfer from animals to humans through direct contact with contaminated environments or vectors. Increased human-animal interaction, which brings people and animals into closer proximity, heightens the risk of zoonotic infections. Additionally, climate change exacerbates this risk by expanding the range of disease vectors and introducing pathogens to new regions. Treatments for monkeypox are designed to manage the zoonotic mpox virus and alleviate symptoms in both humans and potentially infected animals. For example, a report from the UK Health Security Agency in August 2024 indicated 3,732 confirmed cases of mpox in the UK, an increase from 3,753 cases in 2023. This growing prevalence of zoonotic infections is driving demand for monkeypox treatments.

Companies in the monkeypox treatment market are focusing on remote monitoring and teletherapy solutions, such as virtual care, to improve accessibility, streamline patient management, and enhance treatment outcomes. Virtual care for monkeypox involves remote medical consultations, symptom evaluation, and management strategies for individuals at risk or infected, thus facilitating access to care and reducing the need for in-person visits. For instance, in August 2022, Folx Health, a US-based healthcare company, launched Monkeypox Care, a virtual primary care service for those at risk of or affected by monkeypox. This service offers education, counseling, symptom evaluation, and referrals, aiming to reach individuals in underserved areas with limited healthcare access.

In August 2024, Bilthoven Biologicals, a Netherlands-based provider of vaccines and biopharmaceuticals, entered into a partnership with Tonix Pharmaceuticals. The collaboration is focused on accelerating the development of TNX-801, a potential vaccine for preventing mpox, smallpox, and other infectious diseases. Tonix Pharmaceuticals, a US-based pharmaceutical company, is engaged in developing vaccines for monkeypox treatment.

Major companies operating in the monkey pox treatment market are Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Gilead Sciences Inc., BioNTech SE, Moderna Inc., Quest Diagnostics Incorporated, Novavax Inc., Laboratory Corporation of America Holdings, Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Sciences Corporation, Daan Gene Co. Ltd., Sansure Biotech Inc., SIGA Technologies Inc., Elabscience Biotechnology Inc., Mayo Clinic Laboratories, Tonix Pharmaceuticals Holding Corp., Altona Diagnostics GmbH, Lansion Biotechnology Co. Ltd., Goldsite Diagnostics Inc., Chimerix Inc., Emcure Pharmaceuticals Ltd., VBI Vaccines Inc.

North America was the largest region in the monkey pox treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monkey pox treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the monkey pox treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Monkeypox treatment involves medical interventions and therapies designed to manage and alleviate the symptoms of monkeypox, a viral disease caused by the monkeypox virus. These treatments include various therapeutic and supportive approaches aimed at reducing disease severity and enhancing patient outcomes.

The primary types of monkeypox treatment are prophylactic vaccines and therapeutics. Prophylactic vaccines are intended to prevent monkeypox infection by boosting the immune system to recognize and combat the virus, particularly in high-risk populations and during outbreaks to limit the virus's spread. Treatment dosage forms include solid, liquid, and semisolid, with administration routes such as oral, topical, and parenteral. These treatments are distributed through retail pharmacies, hospital pharmacies, and online pharmacies.

The monkey pox treatment market research report is one of a series of new reports that provides monkey pox treatment market statistics, including monkey pox treatment industry global market size, regional shares, competitors with an monkey pox treatment market share, detailed monkey pox treatment market segments, market trends and opportunities, and any further data you may need to thrive in the monkey pox treatment industry. This monkey pox treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The monkey pox treatment market consists of sales of treatment products such as antiviral medications, vaccine administration devices, supportive care products, infection control supplies, and Reagents and assays for monkeypox research and diagnostic development. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.